Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF28996 in Japanese Patients with Parkinson's Disease
NCT06004180Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Lu AF28996 in Parkinson's disease (PD), sponsored by Lundbeck. Primary endpoints: Treatment-emergent Adverse Events, Area Under the Plasma Concentration-Time Curve From Zero to Last Quantifiable Concentration at Day 16 and 3 more. Started Sep 2023; status: completed.
02
Drugs
Lu AF28996
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06004180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06004180.